Takuma Hayashi

ORCID: 0000-0002-7525-2048 · 4 papers in corpus
2023
Molecular Histopathology for Establishing Diagnostic Method and Clinical Therapy for Ovarian Carcinoma.
Journal of clinical medicine research ·doi:10.14740/jocmr4853

Ovarian carcinoma (OC) is considered the deadliest gynecological malignancy. It is typically diagnosed in the advanced stages of the disease, with metastatic sites widely disseminated within the abdominal cavity. OC treatment is challenging…

2022
Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor.
Current oncology (Toronto, Ont.) ·doi:10.3390/curroncol29040190

Background/aimPatients with uterine sarcoma comprise 2-5% of all patients with uterine malignancies; however, the morbidity of uterine sarcoma is low compared with that of other gynecological cancers. For many cases, malignant uterine tumor…

article 2012
Involvement of pelvic inflammation–related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis
Human pathology ·doi:10.1016/j.humpath.2012.02.005

Inflammation in the ovary, including ovulation and pelvic inflammatory disease, has been proposed to play a role in the pathogenesis of ovarian cancer. Endometriotic lesions trigger a local inflammatory reaction and have been reported to be…

article 2012
ISP-4-6 Potential role of LMP2 as anti-oncogenic factor defines new targets for uterine leiomyosarcoma therapy(Group 4 Oncology 4,IS Poster,International Session)